CoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference

CAMBRIDGE, Mass., March 03, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the Cowen &Company 36^th Annual Health Care Conference, taking place March 7-9 at the Boston Marriott Copley Place.

Cowen & Company 36th Annual Health Care Conference  -- CoLucid Presentation Details
Date:	Tuesday, March 8
Time:	8:40am – 9:10am Eastern Time
Location:	Boston Marriott Copley Place, Berkeley Room, 3rd Floor
Webcast:	http://wsw.com/webcast/cowen30/clcd

About CoLucid Pharmaceuticals, Inc.
CoLucid is developing oral lasmiditan for the acute treatment of migraine in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACT
Thomas Mathers                         
Chief Executive Officer             
CoLucid Pharmaceuticals, Inc.  
(781) 365-2596                           

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568